» Promising Proof-of-Concept Data For Lpath’s Ocular Drug Candidate ISONEP(TM) Published DrugInformations.org

« Facial Scars On Men Increase Their AttractivenessAspenBio Pharma Reports On FDA 510(k) Clinical Trial Progress For AppyScore, World’s First Blood-Based Diagnostic Test For Human Appendicitis »

Promising Proof-of-Concept Data For Lpath’s Ocular Drug Candidate ISONEP(TM) Published

Nov 21st 2008Drug InformationEye Health

Lpath, Inc. (OTCBB: LPTN) today announced that the laboratory of Peter Campochiaro, MD at Johns Hopkins University School of Medicine(1) recently published peer-reviewed findings of a research study of iSONEP(TM), Lpath’s Phase 1 anti-S1P antibody, demonstrating promising results in various animal models of ocular disorders. The findings of the study appeared online ahead of print in the

More: continued here

No Comments »

Trackback URI | Comments RSS

You must be logged in to post a comment.

« Medtronic Launches New Medical Device In U.S. To Improve Treatment Of Aortic AneurysmsEarlyLifePeanutConsumptionMightPreventAllergy »

Promising Proof-of-Concept Data For Lpath’s Ocular Drug Candidate ISONEPTM Published

Nov 21st 2008Drug InformationEye Health

Lpath, Inc. (OTCBB: LPTN) today announced that the laboratory of Peter Campochiaro, MD at Johns Hopkins University School of Medicine(1) recently published peer-reviewed findings of a research study of iSONEP?, Lpath’s Phase 1 anti-S1P antibody, demonstrating promising results in various animal models of ocular disorders. The findings of the study appeared online ahead of print in the Journal of Cellular Physiology (

More: continued here

No Comments »

Trackback URI | Comments RSS

You must be logged in to post a comment.